Eledon PharmaceuticalsELDN
ELDN
About: Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Employees: 20
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
3% more funds holding
Funds holding: 32 [Q2] → 33 (+1) [Q3]
2.37% less ownership
Funds ownership: 48.98% [Q2] → 46.61% (-2.37%) [Q3]
8% less capital invested
Capital invested by funds: $49.8M [Q2] → $46M (-$3.77M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16
254%
upside
Avg. target
$16
254%
upside
High target
$16
254%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 22 / 59 met price target | 254%upside $16 | Buy Reiterated | 20 Nov 2024 |
Financial journalist opinion
Based on 3 articles about ELDN published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Positive
Seeking Alpha
3 days ago
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment.
Neutral
GlobeNewsWire
2 weeks ago
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Completed two financings totaling $135 million in combined gross proceeds, with funds expected to support operations through end of 2026 IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced a summary of 2024 accomplishments and provided guidance for anticipated 2025 business milestones.
Neutral
GlobeNewsWire
2 months ago
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Announced oversubscribed $85 million underwritten offering, with proceeds expected to extend cash runway to the end of 2026 IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2024 operating and financial results and reviewed recent business highlights.
Positive
Seeking Alpha
3 months ago
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030.
Neutral
GlobeNewsWire
3 months ago
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant.
Neutral
GlobeNewsWire
3 months ago
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence - Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based immunosuppression - Treatment with tegoprubart was generally well tolerated - Study data to be presented by UChicago Medicine's team in oral presentation at the 5 th IPITA/HSCI/Breakthrough T1D Stem Cells Summit IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes tegoprubart, the Company's investigational anti-CD40L antibody, for prevention of islet transplant rejection in subjects with type 1 diabetes (T1D).
Neutral
GlobeNewsWire
4 months ago
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Neutral
GlobeNewsWire
4 months ago
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Neutral
GlobeNewsWire
5 months ago
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported recent business highlights for its second quarter 2024.
Charts implemented using Lightweight Charts™